Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2009

View Archived Issues

Alnylam presents report on objectives for 2009

Jennerex treats first patients in phase II JX-594 trial for liver cancer

AcelRx reports positive results from NanoTab trial in pain and anxiety

EVP-6124 shows improvement in cognition biomarkers in schizophrenia

Human Genome Sciences provides pipeline update

Vertex updates 2009 clinical development programs in hepatitis C and cystic fibrosis

Algeta completes phase II clinical program for Alpharadin

Cephalon signs option agreement to acquire Ception

Jazz completes enrollment in phase III clinical trial of JZP-6 for fibromyalgia

FDA advisory committee to discuss Dyax's BLA for DX-88 in HAE

InNexus Biotechnology's anticancer candidate DXL-625 safe and effective in primate study

Sygnis presents update on preparations for phase II efficacy trial of AX-200 in acute stroke

Akela achieves milestone payment from Janssen related to phase III study of Taifun

FDA issues complete response letter for Schering-Plough's NDA for Saphris

Savella approved by the FDA for the management of fibromyalgia

Studies point to SRC as a therapeutic target in glioblastoma - and the possible use of dasatinib

Repigmentation of vitiligo seen with tacrolimus 0.1% cream

Amicus Therapeutics presents progress of three lead clinical programs

Kyowa Hakko Kirin to further evaluate KW-6002 in Japan

Cell Therapeutics reports target 2009 milestones

Roche divulges new GPCR-targeting antibodies for diabetes and neurological disorders

Schering-Plough scientists claim new KSP inhibitors with anticancer properties in recent patent

Novel anticancer PI3Kalpha inhibitors developed at GSK

New York University discloses new antimicrobial triazine compounds

New non-nucleoside reverse transcriptase inhibitors prepared and tested at GSK

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...